Literature DB >> 25783691

[Therapy of bone marrow edema syndrome in the knee with denosumab. Case report].

T Geith1, W Mutschler, F Berger.   

Abstract

BACKGROUND: The bone marrow edema syndrome (BMES) is a painful joint disease which usually affects healthy middle aged persons. It is usually treated conservatively. AIM: This case report describes the clinical history of a patient with BMES and a therapy attempt with denosumab. RESULTS AND DISCUSSION: Complete restitution of the bone marrow edema in the knee and the disappearance of clinical complaints were observed 8 weeks after a single therapy with 60 mg denosumab (Prolia®) as a subcutaneous injection. No side-effects of the therapy were noted.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25783691     DOI: 10.1007/s00113-014-2692-2

Source DB:  PubMed          Journal:  Unfallchirurg        ISSN: 0177-5537            Impact factor:   1.000


  22 in total

1.  Treatment of bone marrow edema syndrome with intravenous ibandronate.

Authors:  Christoph Bartl; Andreas Imhoff; Reiner Bartl
Journal:  Arch Orthop Trauma Surg       Date:  2012-10-06       Impact factor: 3.067

Review 2.  Distinguishing transient osteoporosis from avascular necrosis of the hip.

Authors:  J J Guerra; M E Steinberg
Journal:  J Bone Joint Surg Am       Date:  1995-04       Impact factor: 5.284

3.  Bone marrow edema syndrome of the femoral head: treatment with the prostacyclin analogue iloprost vs. core decompression: an MRI-controlled study.

Authors:  Nicolas Aigner; Gert Petje; Wolfgang Schneider; Roland Meizer; Matthias Wlk; Spyridon Kotsaris; Karl Knahr; Franz Landsiedl
Journal:  Wien Klin Wochenschr       Date:  2005-02       Impact factor: 1.704

Review 4.  Calcitonin in the treatment of transient osteoporosis of the hip.

Authors:  Thurayya K Arayssi; Hussein A Tawbi; Ihab M Usta; Mukbil H Hourani
Journal:  Semin Arthritis Rheum       Date:  2003-06       Impact factor: 5.532

5.  Bone marrow edema syndrome in postpartal women: treatment with iloprost.

Authors:  Nicholas Aigner; Roland Meizer; Dominik Meraner; Stephan Becker; Elizabeth Meizer; Franz Landsiedl
Journal:  Orthop Clin North Am       Date:  2009-04       Impact factor: 2.472

6.  Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.

Authors:  Jacques P Brown; Richard L Prince; Chad Deal; Robert R Recker; Douglas P Kiel; Luiz H de Gregorio; Peyman Hadji; Lorenz C Hofbauer; Jose M Alvaro-Gracia; Huei Wang; Matthew Austin; Rachel B Wagman; Richard Newmark; Cesar Libanati; Javier San Martin; Henry G Bone
Journal:  J Bone Miner Res       Date:  2009-01       Impact factor: 6.741

7.  Bone marrow edema and its relation to progression of knee osteoarthritis.

Authors:  David T Felson; Sara McLaughlin; Joyce Goggins; Michael P LaValley; M Elon Gale; Saara Totterman; Wei Li; Catherine Hill; Daniel Gale
Journal:  Ann Intern Med       Date:  2003-09-02       Impact factor: 25.391

8.  Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.

Authors:  Paul D Miller; Michael A Bolognese; E Michael Lewiecki; Michael R McClung; Beiying Ding; Matthew Austin; Yu Liu; Javier San Martin
Journal:  Bone       Date:  2008-04-26       Impact factor: 4.398

Review 9.  Biological agents in management of osteoporosis.

Authors:  Sri Harsha Tella; J Christopher Gallagher
Journal:  Eur J Clin Pharmacol       Date:  2014-09-11       Impact factor: 2.953

10.  Successful treatment of avascular bone necrosis of the knee with neridronate: a case report.

Authors:  A Corrado; L Quarta; S Errico; F P Cantatore
Journal:  Rheumatol Int       Date:  2007-02-07       Impact factor: 3.580

View more
  1 in total

1.  High-energy focused extracorporeal shock wave therapy for bone marrow edema syndrome of the hip: A retrospective study.

Authors:  Leilei Zhang; Yuzhi Cui; Dawei Liang; Jie Guan; Youwen Liu; Xiantao Chen
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.